1372 related articles for article (PubMed ID: 15016559)
41. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
[TBL] [Abstract][Full Text] [Related]
42. Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment.
Konstas AG; Kozobolis VP; Tsironi S; Makridaki I; Efremova R; Stewart WC
Ophthalmology; 2008 Jan; 115(1):99-103. PubMed ID: 18166407
[TBL] [Abstract][Full Text] [Related]
43. 24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension.
Hepsen IF; Ozkaya E
Eye (Lond); 2007 Apr; 21(4):453-8. PubMed ID: 16543930
[TBL] [Abstract][Full Text] [Related]
44. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
Hatanaka M; Reis A; Sano ME; Susanna R
J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
[TBL] [Abstract][Full Text] [Related]
45. Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma.
Chew PT; Aung T; Aquino MV; Rojanapongpun P;
Ophthalmology; 2004 Mar; 111(3):427-34. PubMed ID: 15019314
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.
Schuman JS; Katz GJ; Lewis RA; Henry JC; Mallick S; Wells DT; Sullivan EK; Landry TA; Bergamini MV; Robertson SM
Am J Ophthalmol; 2005 Aug; 140(2):242-50. PubMed ID: 16086946
[TBL] [Abstract][Full Text] [Related]
47. Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/timolol versus latanoprost or timolol monotherapy.
Varma R; Hwang LJ; Grunden JW; Bean GW
Br J Ophthalmol; 2010 Jan; 94(1):80-4. PubMed ID: 19692375
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy.
Stewart WC; Stewart JA; Day DG; Sharpe ED; Jenkins JN
Eye (Lond); 2004 Oct; 18(10):990-5. PubMed ID: 15037890
[TBL] [Abstract][Full Text] [Related]
49. Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials.
Varma R; Hwang LJ; Grunden JW; Bean GW
Am J Ophthalmol; 2008 Feb; 145(2):336-42. PubMed ID: 18222194
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of timolol solution once daily versus timolol gel in treating elevated intraocular pressure.
Stewart WC; Leland TM; Cate EA; Stewart JA
J Glaucoma; 1998 Dec; 7(6):402-7. PubMed ID: 9871862
[TBL] [Abstract][Full Text] [Related]
51. Effects of the combination of bimatoprost and latanoprost on intraocular pressure in primary open angle glaucoma: a randomised clinical trial.
Doi LM; Melo LA; Prata JA
Br J Ophthalmol; 2005 May; 89(5):547-9. PubMed ID: 15834081
[TBL] [Abstract][Full Text] [Related]
52. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
[TBL] [Abstract][Full Text] [Related]
53. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group.
Bucci MG
J Glaucoma; 1999 Feb; 8(1):24-30. PubMed ID: 10084271
[TBL] [Abstract][Full Text] [Related]
54. Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma.
Konstas AG; Mylopoulos N; Karabatsas CH; Kozobolis VP; Diafas S; Papapanos P; Georgiadis N; Stewart WC
Eye (Lond); 2004 Sep; 18(9):893-9. PubMed ID: 15002024
[TBL] [Abstract][Full Text] [Related]
55. A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients.
Martin E; Martinez-de-la-Casa JM; Garcia-Feijoo J; Troyano J; Larrosa JM; Garcia-Sanchez J
Eye (Lond); 2007 Feb; 21(2):164-8. PubMed ID: 16254590
[TBL] [Abstract][Full Text] [Related]
56. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.
Parrish RK; Palmberg P; Sheu WP;
Am J Ophthalmol; 2003 May; 135(5):688-703. PubMed ID: 12719078
[TBL] [Abstract][Full Text] [Related]
57. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
Noecker RJ; Walt JG
Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
[TBL] [Abstract][Full Text] [Related]
58. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma.
Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M
Curr Med Res Opin; 2005 Nov; 21(11):1875-83. PubMed ID: 16307709
[TBL] [Abstract][Full Text] [Related]
59. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
60. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.
Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M
Curr Med Res Opin; 2006 May; 22(5):897-905. PubMed ID: 16709311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
